MP-MUS, which is a prodrug activated by MAOB, reduces the proliferation of glioma cells, and Danshensu, which is an MAOB inhibitor, increases the radiosensitivity of non-small cell lung cancer [63,64]. This evidence concerns the gene MAOB and glioma.